Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Duloxetine SCHEMBL1200511 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3398599 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29355040 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30003730 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL30197067 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508519-A1 | \"Process for the preparation of duloxetine and its hydrochloride salt\ | Bioindustria Laboratorio Italiano Medicinali S.p.A In forma abbreviata Bioindustria L.I.M. S.p.A. (IT) | 2012-10-10 | — | — | EP | claimed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | claimed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | claimed |
| US-20220273637-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Institut National de la Santé et de la Recherche Médicale (FR) | 2022-09-01 | — | — | US | disclosed |
| US-20220265659-A1 | METHODS AND COMPOSITIONS FOR TREATING PAX6-DEFICIENCY RELATED DISEASE | UNIVERSITÉ PARIS CITÉ (FR) | 2022-08-25 | — | — | US | disclosed |
| EP-4025206-A1 | METHODS AND COMPOSITIONS FOR TREATING PAX6- DEFICIENCY RELATED DISEASE | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-07-13 | — | — | EP | disclosed |
| EP-3838899-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF | Shanghai Leado Pharmatech Co. Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021043723-A1 | METHODS AND COMPOSITIONS FOR TREATING PAX6- DEFICIENCY RELATED DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-03-11 | — | — | WO | disclosed |
| WO-2020228789-A1 | 3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | 上海璃道医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-20200230132-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | NATIONAL INSTITUTES OF HEALTH | 2020-07-23 | — | — | US | disclosed |
| US-9913838-B2 | Methods of treating cancer using compositions comprising perillyl alcohol derivative | Neonc Technologies, Inc. (US) | 2018-03-13 | — | — | US | disclosed |
| WO-2007038253-A2 | DNT-MALEATE AND METHODS OF PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-05 | — | — | WO | disclosed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070004795-A1 | Antidepressant oral pharmaceutical compositions | NANOCRYSTAL ASIA INC. (TW) | 2007-01-04 | — | — | US | disclosed |
| US-20070004795-A1 | Antidepressant oral pharmaceutical compositions | NANOCRYSTAL ASIA INC. (TW) | 2007-01-04 | — | — | US | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230132-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | POLH, PLIN3, POLE3 | SLC6A4 4302/4885SLC6A2 4159/4885SLC6A3 2515/4885 |
| US-20220265659-A1 | METHODS AND COMPOSITIONS FOR TREATING PAX6-DEFICIENCY RELATED DISEASE | MITF, PAX3, RB1 | SLC6A4 797/4885SLC6A2 1678/4885SLC6A3 481/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SLC6A4 3269/4885SLC6A2 3188/4885SLC6A3 3683/4885 |
| US-20070004795-A1 | Antidepressant oral pharmaceutical compositions | SLC6A4, SLC5A1, SLC5A2 | SLC6A4 1/4885SLC6A2 6/4885SLC6A3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.